CoChat

Testosterone deficiency in non-cancer opioid-treated patients

Open access
Coluzzi, F., Billeci, D., Maggi, M., Corona, G. · 2018 · Journal of Endocrinological Investigation
Cited by 81

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Purpose: The use of opioids in patients with chronic non-cancer pain is common and can be associated with opioid-induced androgen deficiency (OPIAD) in men. This review aims to evaluate the current literature regarding the prevalence, clinical consequence and management of OPIAD. Methods: A database search was performed in Medline, Embase and Cochrane using terms such as “analgesics”, “opioids” and “testosterone”. Relevant literature from January 1969 to March 2018 was evaluated. Results: The prevalence of patients with OPIAD ranges from 19 to 86%, depending on the criteria for diagnosis of hypogonadism. The opioid-induced suppression of gonadotropin-releasing and luteinizing hormones represents the main important pathogenetic mechanisms. OPIAD has significant negative clinical consequences on sexual function, mood, bone density and body composition. In addition, OPIAD can also impair pain control leading to hyperalgesia, which can contribute to sexual dysfunction and mood impairment. Conclusions: OPIAD is a common adverse effect of opioid treatment and contributes to sexual dysfunction, impairs pain relief and reduces overall quality of life. The evaluation of serum testosterone levels should be considered in male chronic opioid users and the decision to initiate testosterone treatment should be based on the clinical profile of individuals, in consultation with the patient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40618-018-0964-3

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 109

  1. Phillips CJ (2009) The cost and burden of chronic pain. Rev Pain 3(1):2–5 · DOI · Paper page
  2. Coluzzi F (2017) “I am in pain”: is it really the magic formula to open the door of opioid abuse? Minerva Anestesiol 83(12):1332–1333 · DOI
  3. Kress HG, Ahlbeck K, Aldington D et al (2014) Managing chronic pain in elderly patients requires a change of approach. Curr Med Res Opin 30(6):1153–1164 · DOI
  4. Ambrosio F, Finco G, Mattia C et al (2006) SIAARTI chronic non-cancer pain study group. Minerva Anestesiol 72:80–859
  5. Chou R, Fanciullo GJ, Fine PG et al (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10(2):113–30. e22 · DOI · Paper page
  6. Manchikanti L, Abdi S, Atluri S et al (2012) American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2–guidance. Pain Phys 15(3 Suppl):S67–S116
  7. Mattia C, Di Bussolo E, Coluzzi F (2012) Non-analgesic effects of opioids: the interaction of opioids with bone and joints. Curr Pharm Des 18(37):6005–6009 · DOI
  8. Coluzzi F, Rocco A, Mandatori I et al (2012) Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation. Curr Pharm Design. 18(37):6043–6052 · DOI
  9. Kumar L, Barker C, Emmanuel A (2014) Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroent Res Pract 2014:141737 · DOI
  10. Corona G, Vignozzi L, Sforza A et al (2013) Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Men’s Health 31(2):103–125 · DOI
  11. Corona G, Maseroli E, Rastrelli G et al (2016) Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Minerva Endocrinol 41(2):196–210
  12. Brennan MJ (2013) The effect of opioid therapy on endocrine function. Am J Med 126(3):S12–S18 · DOI
  13. Aloisi AM, Aurilio C, Bachiocco V et al (2009) Endocrine consequences of opioid therapy. Psychoneuroendocrino 34(Suppl 1):S162–S168 · DOI · Paper page
  14. Smith HS, Elliott JA (2012) Opioid-induced androgen deficiency (OPIAD). Pain Phys 15(3 Suppl):145–156
  15. Grossmann M, Matsumoto AM (2017) A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocr Metab 102(3):1067–1075 · DOI · Paper page
  16. Pathan H, Williams J (2012) Basic opioid pharmacology: an update. Br J Pain 6(1):11–16 · DOI · Paper page
  17. Stein C, Schäfer M, Machelska H (2003) Attacking pain at its source: new perspectives on opioids. Nat Med 9(8):1003 · DOI · Paper page
  18. Corbett AD, Henderson G, McKnight AT et al (2006) 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 147(S1):S153–S162 · DOI · Paper page
  19. Schwarzer C (2009) 30 years of dynorphins—new insights on their functions in neuropsychiatric diseases. Pharmacol Ther 123(3):353–370 · DOI · Paper page
  20. McDonald J, Lambert D (2005) Opioid receptors. Contin Educ Anaesth Crit Care Pain 5(1):22–25 · DOI
  21. Coluzzi F, Taylor R Jr, Pergolizzi JV Jr et al (2016) Good clinical practice guide for opioids in pain management: the three Ts—titration (trial), tweaking (tailoring), transition (tapering). Braz J Anesthesiol 66(3):310–317 · DOI
  22. Daubresse M, Chang HY, Yu Y et al (2013) Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010. Med Care 51(10):870–878 · DOI · Paper page
  23. Lurcott G (1998) The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone. Anesth Prog 45(4):154
  24. Mattia C, Coluzzi F (2015) A look inside the association codeine-paracetamol: clinical pharmacology supports analgesic efficacy. Eur Rev Med Pharmacol Sci 19(3):507–516
  25. Dayer P, Collart L, Desmeules J (1994) The pharmacology of tramadol. Drugs 47(1):3–7 · DOI · Paper page
  26. Mattia C, Coluzzi F (2005) Tramadol. Focus on musculoskeletal and neuropathic pain. Minerva Anestesiol 71(10):565–584
  27. Mattia C, Coluzzi F (2006) Once-daily tramadol in rheumatological pain. Expert Opin Pharmacother 7(13):1811–1823 · DOI
  28. Coluzzi F, Mattia C (2007) Chronic non-cancer pain: focus on once-daily tramadol formulations. Ther Clin Risk Manag 3(5):819–829
  29. Mattia C, Coluzzi F, Sarzi Puttini P et al (2008) Paracetamol/Tramadol association: the easy solution for mild-moderate pain. Minerva Med 99(4):369–390
  30. Trescot AM, Datta S, Lee M et al (2008) Opioid pharmacology. Pain Physician 11(2 Suppl):S133–S153 · DOI · Paper page
  31. Ghelardini C, Mannelli LDC, Bianchi E (2015) The pharmacological basis of opioids. Clin Cases Miner Bone Metabol 12(3):219
  32. Coluzzi F, Mattia C (2005) Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol 71(7–8):451–460
  33. Nielsen CK, Ross FB, Lotfipour S et al (2007) Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 132(3):289–300 · DOI · Paper page
  34. Kim ES (2017) Oxycodone/naloxone prolonged release: a review in severe chronic pain. Clin Drug Investig 37(12):1191–1201 · DOI
  35. Baron R, Jansen JP, Binder A et al (2016) Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 trial. Pain Pract 16(5):600–619 · DOI
  36. Coluzzi F, Mattia C (2010) OROS(R) hydromorphone in chronic pain management: when drug delivery technology matches clinical needs. Minerva Anestesiol 76(12):1072–1084
  37. Scholz J, Steinfath M, Schulz M (1996) Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. Clin Pharmacokinet 31(4):275–292 · DOI · Paper page
  38. Kornick CA, Santiago-Palma J, Moryl N et al (2003) Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 26(13):951–973 · DOI
  39. Rubinstein AL, Carpenter DM (2017) Association between commonly prescribed opioids and androgen deficiency in men: a retrospective cohort analysis. Pain Med 18(4):637–644 · DOI · Paper page
  40. Coluzzi F, Fornasari D, Pergolizzi J et al (2017) From acute to chronic pain: tapentadol in the progressive stages of this disease entity. Eur Rev Med Pharmacol Sci 21(7):1672–1683
  41. Pergolizzi JV Jr, Breve F, Taylor R Jr et al (2017) Considering tapentadol as a first-line analgesic: 14 questions. Pain Manag 7(4):331–339 · doi:10.2217/pmt-2016-0063
  42. Billeci D, Coluzzi F (2017) Tapentadol extended release for the management of chronic neck pain. J Pain Res 10:495–505 · DOI
  43. Pergolizzi JV Jr, Taylor R Jr, LeQuang JA et al (2018) Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain. Pain Ther 7:37–57 · DOI
  44. Vadivelu N, Kai A, Maslin B et al (2015) Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Ther Clin Risk Manag 11:95–105 · DOI · Paper page
  45. Coluzzi F, Ruggeri M (2014) Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin 30(6):1139–1151 · DOI
  46. Ide S, Minami M, Satoh M et al (2004) Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in μ-opioid receptor knockout mice. Neuropsychopharmacology 29(9):1656 · DOI
  47. Pergolizzi JV, Coluzzi F, Taylor R (2018) Transdermal buprenorphine for moderate chronic noncancer pain syndromes. Expert Rev Neurother 18(5):359–369 · DOI
  48. Coluzzi F, Bifulco F, Cuomo A et al (2017) The challenge of perioperative pain management in opioid-tolerant patients. Ther Clin Risk Manag 13:1163–1173 · DOI
  49. Azizi F, Vagenakis AG, Longcope C et al (1973) Decreased serum testosterone concentration in male heroin and methadone addicts. Steroids 22(4):467–472 · DOI
  50. Cicero TJ, Bell RD, Wiest WG et al (1975) Function of the male sex organs in heroin and methadone users. N Engl J Med 292(17):882–887 · DOI · Paper page
  51. Drobnis EZ, Nangia AK (2017) Antivirals and male reproduction. Adv Exp Med Biol 1034:163–178 · doi:10.1007/978-3-319-69535-8_11
  52. Roberts LJ, Finch PM, Pullan PT et al (2002) Sex hormone suppression by intrathecal opioids: a prospective study. Clin J Pain 18(3):144–148 · DOI · Paper page
  53. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL et al (2003) Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manag 26(5):1055–1061 · DOI
  54. Dudley U, Duarte RV (2013) Prevalence and influence of diagnostic criteria in the assessment of hypogonadism in intrathecal opioid therapy patients. Pain Physician 16:9–14
  55. Rubinstein AL, Carpenter DM, Minkoff JR (2013) Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids. Clin J Pain 29(10):840–845 · DOI · Paper page
  56. Ajo R, Segura A, Inda MM et al (2016) Opioids increase sexual dysfunction in patients with non-cancer pain. J Sex Med 13(9):1377–1386 · DOI
  57. Cepeda MS, Zhu V, Vorsanger G et al (2015) Effect of opioids on testosterone levels: cross-sectional study using NHANES. Pain Med 16(12):2235–2242 · DOI
  58. Kim CH, Garcia R, Stover J et al (2014) Androgen deficiency in long-term intrathecal opioid administration. Pain Physician 17(4):543–548 · DOI
  59. Elliott JA, Horton E, Fibuch EE (2011) The endocrine effects of long-term oral opioid therapy: a case report and review of the literature. J Opioid Manag 7(2):145–154 · DOI · Paper page
  60. Eichenbaum G, Gohler K, Etropolski M et al (2015) Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency. J Opioid Manag 11(3):211–227 · DOI
  61. Corona G, Giagulli VA, Maseroli E et al (2016) Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest 39(9):967–981 · DOI · Paper page
  62. Corona G, Giorda C, Cucinotta D et al (2013) The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. J Endocrinol Invest 36(10):864–868
  63. Kelly D, Jones T (2015) Testosterone and obesity. Obes Rev 16(7):581–606 · DOI · Paper page
  64. Wiesner J, Koenig J, Krulich L et al (1984) Site of action for β-endorphin-induced changes in plasma luteinizing hormone and prolactin in the ovariectomized rat. Life Sci 34(15):1463–1473 · DOI
  65. Li S, Pelletier G (1993) Opioid regulation of gonadotropin-releasing hormone gene expression in the male rat brain as studied by in situ hybridization. NeuroReport 4(3):331–333 · DOI
  66. Gabriel SM, Simpkins JW, Kalra SP et al (1985) Chronic morphine treatment induces hypersensitivity to testosterone-negative feedback in castrated male rats. Neuroendocrinology 40(1):39–44 · DOI
  67. Aloisi AM, Ceccarelli I, Fiorenzani P et al (2010) Aromatase and 5-alpha reductase gene expression: modulation by pain and morphine treatment in male rats. Mol Pain 6(1):69
  68. Rosa M, de la Raymond E, Hennessey M, James V (1996) Hypogonadism and methadone: hypothalamic hypogonadism after long-term use of high-dose methadone. Endocr Pract 2(1):4–7 · DOI
  69. Petraglia F, Bernasconi S, Iughetti L et al (1986) Naloxone-induced luteinizing hormone secretion in normal, precocious, and delayed puberty. J Clin Endocrinol Metab 63(5):1112–1116 · DOI
  70. Vermeulen A, Deslypere JP, Kaufman JM (1989) Influence of antiopioids on luteinizing hormone pulsatility in aging men. J Clin Endocrinol Metab 68(1):68–72 · DOI · Paper page
  71. Rastrelli G, Giovannini L, Calogero A et al (2016) Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry. J Endocrinol Invest 39(6):695–708 · DOI
  72. Corona G, Bianchini S, Sforza A et al (2015) Hypogonadism as a possible link between metabolic diseases and erectile dysfunction in aging men. Hormones (Athens) 14(4):569–578 · DOI
  73. Maseroli E, Corona G, Rastrelli G et al (2015) Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med 12(4):956–965 · DOI · Paper page
  74. Lamm S, Chidakel A, Bansal R (2016) Obesity and hypogonadism. Urol Clin 43(2):239–245 · DOI
  75. Isidori AM, Balercia G, Calogero A et al (2015) Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest 38(1):103–112 · DOI · Paper page
  76. Lee KS, Zhang Y, Asgar J et al (2016) Androgen receptor transcriptionally regulates μ-opioid receptor expression in rat trigeminal ganglia. Neuroscience 331:52–61 · DOI
  77. Corona G, Isidori AM, Aversa A et al (2016) Endocrinologic control of men’s sexual desire and arousal/erection. J Sex Med 13(3):317–337 · DOI · Paper page
  78. Ambler N, de Williams AC, Hill P et al (2001) Sexual difficulties of chronic pain patients. Clin J Pain 17(2):138–145 · DOI · Paper page
  79. Tajar A, O’Neill TW, Lee DM et al (2011) The effect of musculoskeletal pain on sexual function in middle-aged and elderly European men: results from the European male ageing study. J Rheumatol 38(2):370–377 · DOI
  80. Carosa E, Benvenga S, Trimarchi F et al (2002) Sexual inactivity results in reversible reduction of LH bioavailability. Int J Impot Res 14(2):93–99 (Discussion 100) · DOI
  81. Carosa E, Martini P, Brandetti F et al (2004) Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol 61(3):382–386 · DOI
  82. Fabbri A, Jannini EA, Gnessi L et al (1989) Neuroendocrine control of male reproductive function. The opioid system as a model of control at multiple sites. J Steroid Biochem 32(1B):145–150 · DOI
  83. Fabbri A, Jannini EA, Ulisse S et al (1988) Low serum bioactive luteinizing hormone in nonorganic male impotence: possible relationship with altered gonadotropin-releasing hormone pulsatility. J Clin Endocrinol Metab 67(5):867–875 · DOI
  84. Fabbri A, Jannini EA, Gnessi L et al (1989) Endorphins in male impotence: evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinology 14(1–2):103–111 · DOI
  85. Deyo RA, Smith DH, Johnson ES et al (2013) Prescription opioids for back pain and use of medications for erectile dysfunction. Spine 38(11):909 · DOI
  86. Davis MP, Mehta Z (2016) Opioids and chronic pain: where is the balance? Curr Oncol Rep 18(12):71 · DOI
  87. Smith K, Mattick RP, Bruno R et al (2015) Factors associated with the development of depression in chronic non-cancer pain patients following the onset of opioid treatment for pain. J Affect Disord 184:72–80 · DOI
  88. Smith JB, Rosen J, Colbert A (2018) Low serum testosterone in outpatient psychiatry clinics: addressing challenges to the screening and treatment of hypogonadism. Sex Med Rev 6(1):69–76 · DOI
  89. Rastrelli G, Maggi M, Corona G (2018) Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol 11:439–458 · DOI · Paper page
  90. Rochira V, Antonio L, Vanderschueren D (2018) EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology 6(2):272–285 · DOI · Paper page
  91. Vestergaard P, Rejnmark L, Mosekilde L (2006) Fracture risk associated with the use of morphine and opiates. J Intern Med 260(1):76–87 · DOI · Paper page
  92. Saunders KW, Dunn KM, Merrill JO et al (2010) Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med 25(4):310–315 · DOI · Paper page
  93. Højsted J, Ekholm O, Kurita GP et al (2013) Addictive behaviors related to opioid use for chronic pain: a population-based study. Pain 154(12):2677–2683 · DOI
  94. Birke H, Kurita G, Sjøgren P et al (2016) Chronic non-cancer pain and the epidemic prescription of opioids in the Danish population: trends from 2000 to 2013. Acta Anaesth Scand 60(5):623–633 · DOI · Paper page
  95. Nogueiras R, Romero-Picó A, Vazquez MJ et al (2012) The opioid system and food intake: homeostatic and hedonic mechanisms. Obes Facts 5(2):196–207 · DOI
  96. Corona G, Maseroli E, Maggi M (2014) Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacol 15(13):1903–1926 · DOI · Paper page
  97. Francomano D, Bruzziches R, Barbaro G et al (2014) Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest 37(4):401–411 · DOI
  98. Corona G, Sforza A, Maggi M (2017) Testosterone replacement therapy: long-term safety and efficacy. World J Mens Health 35(2):65–76 · DOI · Paper page
  99. Corona G, Dicuio M, Rastrelli G et al (2017) Testosterone treatment and cardiovascular and venous thromboembolism risk: what is ‘new’? J Invest Med 65:964–973 · DOI · Paper page
  100. Anawalt BD, Yeap BB (2018) Conclusions about testosterone therapy and cardiovascular risk. Asian J Androl 20(2):152 · DOI
  101. Corona G, Rastrelli G, Maseroli E et al (2014) Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology 2(5):741–747 · DOI
  102. Corona G, Rastrelli G, Monami M et al (2011) Body mass index regulates hypogonadism-associated CV risk: results from a cohort of subjects with erectile dysfunction. J Sex Med 8(7):2098–2105 · DOI · Paper page
  103. Li L, Setoguchi S, Cabral H et al (2013) Opioid use for noncancer pain and risk of myocardial infarction amongst adults. J Intern Med 273(5):511–526 · DOI · Paper page
  104. Mendelson JH, Mendelson JE, Patch VD (1975) Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther 192(1):211–217 · DOI · Paper page
  105. Basaria S, Travison TG, Alford D et al (2015) Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain 156(2):280–288 · DOI · Paper page
  106. Blick G, Khera M, Bhattacharya RK et al (2012) Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS). Pain Med 13(5):688–698 · DOI · Paper page
  107. Corona G, Rastrelli G, Morgentaler A et al (2017) Meta-analysis of results of testosterone therapy on sexual function based on International Index of Erectile Function Scores. Eur Urol 72(6):1000–1011 · DOI · Paper page
  108. Corona G, Ratrelli G, Maggi M (2015) The pharmacotherapy of male hypogonadism besides androgens. Expert Opin Pharmacol 16(3):369–387 · DOI · Paper page
  109. Corona G, Rastrelli G, Reisman Y et al (2018) The safety of available treatments of male hypogonadism in organic and functional hypogonadism. Expert Opin Drug Saf 17:277–292 · DOI

Cited by

See all 81

Metadata

Authors
Coluzzi, F., Billeci, D., Maggi, M., & Corona, G.
Venue
Journal of Endocrinological Investigation
Published
2018-10-20
Volume
41
Issue
12
Pages
1377-1388
ISSN
  • 0391-4097 (ISSN-L)
  • 1720-8386
OpenAlex
W2897436693
Cited by
81
References
28
FWCI
6.65
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Testosterone deficiency in non-cancer opioid-treated patients. https://app.cochat.ai/papers/10.1007/s40618-018-0964-3
The paper
Coluzzi, F., Billeci, D., Maggi, M., & Corona, G. (2018). Testosterone deficiency in non-cancer opioid-treated patients. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-018-0964-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.